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BACKGROUND AND PURPOSE
NMDA receptors play a key role in both synaptic plasticity and neurodegeneration. Adenosine is an endogenous neuromodulator
and through membrane receptors of the A2A subtype can influence both synaptic plasticity and neuronal death. The present work
was designed to evaluate the influence of adenosine A2A receptors upon NMDA receptor activity in CA1 hippocampal neurons.
We discriminated betweenmodulation of synaptic versus extrasynaptic receptors, since extrasynaptic NMDA receptors are mostly
associated with neurodegeneration while synaptic NMDA receptors are linked to plasticity phenomena.
EXPERIMENTAL APPROACH
Whole-cell patch-clamp recordings were obtained to evaluate NMDA receptor actions on CA1 pyramidal neurons of young adult
(5–10 weeks) male Wistar rat hippocampus.
KEY RESULTS
Activation of A2A receptors with CGS 21680 (30 nM) consistently facilitated chemically-evoked NMDA receptor-currents (NMDA-
PSCs) and afferent-evoked NMDA-currents (NMDA-EPSCs), an action prevented by an A2A receptor antagonist (SCH58261,
100 nM) and a PKA inhibitor, H-89 (1 μM). These actions did not reflect facilitation in glutamate release since there was no change
in NMDA-EPSCs paired pulse ratio. A2A receptor actions were lost in the presence of an open-channel NMDA receptor blocker,
MK-801 (10 μM), but persisted in the presence of memantine, at a concentration (10 μM) known to preferentially block
extrasynaptic NMDA receptors.
CONCLUSION AND IMPLICATIONS
These results show that A2A receptors exert a positive postsynaptic modulatory effect over synaptic, but not extrasynaptic, NMDA
receptors in CA1 neurons and, therefore, under non-pathological conditions may contribute to shift the dual role of NMDA re-
ceptors towards enhancement of synaptic plasticity.
Abbreviations
aCSF, artificial CSF; CaMKII, Ca2+/calmodulin-dependent protein kinase II; CGS 21680, 2-[4-(2-p-carboxyethyl)
phenylamino]-50N-ethylcarbozamido adenosine; CNQX, 6-cyano-7-nitroquinoxaline-2,3-dione; DL-AP5, 2-amino-5-
phosphonovaleric acid; LTD, long-term depression; memantine, 3,5-dimethyl-1-adamantanamine hydrochloride; PPR,
paired pulse ratio; SCH 58261, 7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine;
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Introduction
NMDA receptors are membrane-bound ionotropic gluta-
mate receptors characterized by voltage-dependent activity,
high permeability to calcium ions and slow activation/
deactivation kinetics (Doherty and Sladek, 2011). Calcium
influx through NMDA receptors is crucial for synaptogenesis,
experience-dependent synaptic remodelling and for long-
lasting changes in synaptic efficiency such as LTP and long-
term depression (LTD). Indeed, NMDA receptors are key
components in the induction of several forms of synaptic
plasticity (Hunt and Castillo, 2012). Following depolariza-
tion of the postsynapticmembrane and release of magnesium
blockade, a postsynaptic rise in calcium, mediated by the
opening of NMDA receptors, activates important kinases
such as calmodulin-dependent kinase II (CaMKII),
PKA and PKC (Lau and Zukin, 2007), with an impact on
synaptic reinforcement through fast signalling AMPA
receptors at the postsynaptic membrane (Malenka and
Nicoll, 1999; Morris et al., 2003; Collingridge et al., 2004).
On the other hand, NMDA receptors are the main mediators
of excitotoxicity, whenever there is an excessive and neuro-
toxic increase in intracellular calcium (Hardingham and
Bading, 2010). The dual role of the NMDA receptor is related
to receptor location relative to the synapse (Hardingham and
Bading, 2010). Calcium influx through synaptic NMDA
receptors is relatively well tolerated by neuronal cells and
important for neuronal survival and synaptic plasticity, while
an influx through extrasynaptic NMDA receptors is linked to
neurotoxicity (Hardingham et al., 2002). Regulatory
mechanisms that control NMDA receptor activity at specific
membrane locations are, therefore, of particular importance
and its knowledge relevant for strategies aiming to favour
the balance towards neuronal survival and shape synaptic
functioning.
Adenosine is an ubiquitous neuromodulator influenc-
ing the action and activity of several neurotransmitter
receptors (Sebastião and Ribeiro, 2015). Adenosine A1
receptors are responsible for the adenosine-mediated inhib-
itory effects, including inhibition of neurotransmitter release
and changes in postsynaptic membrane conductance
(Dunwiddie and Masino, 2001), as well as inhibition of
NMDA receptor-mediated currents at hippocampal neurons
(De Mendonça et al., 1995). The other subtype of high-
affinity adenosine receptors, the adenosine A2A receptor,
is coupled to Gs proteins, classically leading to stimulation
of adenylate cyclase, a rise in intracellular cAMP levels and
PKA activation. A2A receptors are mostly expressed in the
basal ganglia but are also expressed in lower levels at the
hippocampus where they exert important neuromodulatory
actions such as the control of other modulators (Sebastião
and Ribeiro, 2015) and regulate synaptic plasticity (Dias
et al., 2013a). Indeed, adenosine A2A receptors at the CA1 area
of the hippocampus enhance LTP (Costenla et al., 2011; Dias
et al., 2012), facilitate the actions of the brain-derived neuro-
trophic factor (BDNF) at hippocampal synapses (Diógenes
et al., 2004; Fernandes et al., 2008) with consequences for
synaptic plasticity (Fontinha et al., 2008), and enhance
AMPA-evoked currents recorded from CA1 pyramidal
neurons (Dias et al., 2012) with an impact on ischaemia-
induced plasticity phenomena (Dias et al., 2013b). Also, the
degree of activation of A2A receptors affects hippocampal-
dependent learning (Fontinha et al., 2009; Batalha et al.,
2013), excitotoxicity and neuronal death (Jones et al., 1998;
Cunha, 2016; Ribeiro et al., 2016).
The activity of A2A receptors regulates the function of
NMDA receptors in the striatum (Wirkner et al., 2004) and
plays a permissive role in the positive interaction between
metabotropic glutamate receptors 5 (mGlu5 receptors) and
NMDA receptors in the hippocampus (Tebano et al., 2005;
Sarantis et al., 2015; Kouvaros and Papatheodoropoulos,
2016; Krania et al., 2018), an action recently shown to be in-
volved in synaptic plasticity deregulation under conditions
of presynaptic A2A receptor overexpression (Temido-Ferreira
et al., 2018). A2A receptors’ activity is also required to gate a
form of LTP mediated by postsynaptic NMDA receptors at
mossy fibre hippocampal synapses (Rebola et al., 2008). How-
ever, despite the dual role of NMDA receptors, as well as of A2A
receptors upon LTP and excitotoxicity, no information so far
exists on the direct influence of A2A receptors on NMDA
receptor-mediated currents. This issue is particularly impor-
tant and needs to be investigated in the CA1 area of the
hippocampus, given the major role of NMDA receptors in
CA1 LTP and the vulnerability of this hippocampal area to
excitotoxicity phenomena.
We herein evaluated whether activation of adenosine
A2A receptors could affect NMDA receptor-mediated currents
in CA1 pyramidal cells. Given the differences between
synaptic and extrasynaptic NMDA receptor-mediated activ-
ity upon neuronal function (Hardingham and Bading,
2010), we focused on distinguishing if any action produced
by A2A receptors detected mostly resulted from modulation
of synaptic or extrasynaptic NMDA receptor-mediated
currents.
Methods
Hippocampal slice preparation and
patch-clamp procedures
Animal studies are reported in compliance with the
ARRIVE guidelines (Kilkenny et al., 2010). All experiments
were carried out on acute hippocampal slices obtained from
5- to 10-week-old male Wistar rats (Harlan Iberica,
Spain). All experiments followed the European Community
Guidelines (Directive 2010/63/EU) and the Portuguese Law
(DL 113/2013) for Animal Care for Research Purposes, and
were approved by the “Instituto de Medicina Molecular”
Internal Committee and the Portuguese Animal Ethics
Committee - Direcção Geral de Veterinária.
The animals were killed by decapitation under deep
isoflurane anaesthesia. The brain was quickly removed,
hemisected, and both hippocampi used to obtain transverse
slices (300-μm-thick) cut on a Vibratome (VT 1000S; Leica,
Nussloch, Germany) in ice-cold dissecting solution contain-
ing (in mM): sucrose 110; KCl 2.5; CaCl2 0.5; MgCl2 7;
NaHCO3 25; NaH2PO4 1.25; glucose 7, bubbled with 95%
O2 and 5% CO2, pH 7.4. Slices were first incubated for
30min at 35°C in artificial CSF (aCSF) containing (mM): NaCl
124; KCl 3; NaH2PO4 1.25; NaHCO3 26; MgSO4 1; CaCl2 2
and glucose 10, pH 7.4, gassed with 95% O2 and 5% CO2;
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after recovery for at least 1 h at room temperature, individual
slices were set up for electrophysiological recordings.
Throughout the recording period, the aCSF was supple-
mented with 5 μM glycine and no Mg2+ was added.
Individual slices were fixed with a grid in a recording
chamber and continuously superfused by a gravitational
superfusion system at 2–3 mL·min1 with aCSF (with
glycine and no Mg2+) at room temperature. Unless stated
otherwise, drugs were added to the superfusion solution.
Zero minutes in the figures correspond to the time when
the first test solution was changed and indicate time at
which the transfer was initiated. Around 2–3 min elapsed be-
fore the new solution reached the recording chamber; it took
several minutes before the final concentration of the test
drug was achieved in the recording chamber (dead volume
of the recording chamber plus perfusion tubing: 10 mL).
Patch pipettes (4–9 MΩ) were pulled from borosilicate
glass capillaries (1.5 mm outer diameter, 0.86 inner diameter,
Harvard Apparatus), with a PC-10 Puller (Narishige
Group) and filled with an intracellular solution containing
(mM): K-gluconate 125; KCl 11; CaCl2 0.1; MgCl2 2; EGTA
1; HEPES 10; MgATP 2; NaGTP 0.3 and phosphocreatine 10,
pH 7.3, adjusted with KOH (1 M), 280-290 mOsm.
Electrode positioning and cell selection were performed
under visual guidance using a Carl Zeiss Axioskop 2FS upright
microscope (Jena, Germany) equipped with a differential
interference contrast-infrared (DIC-IR) CCD video camera
(VX44, Till Photonics, Gräfelfing, Germany).
Recordings were performed in voltage-clamp mode
(Vh = 60 mv) with an EPC-7 amplifier (List Biologic, Camp-
bell, CA) or Axopatch 200B amplifier (Axon Instruments, CA,
USA). The junction potential was not compensated for, and
offset potentials were nulled before giga-seal formation.
Small voltage steps (5 mV, 50 ms) were delivered throughout
the experiment to monitor the access resistance; the holding
current was also constantly monitored, and when any of
these parameters varied by more than 20%, the experiment
was rejected. The current signal was low-pass filtered using a
3 and 10 kHz three-pole Bessel filter, digitized at 10 kHz using
a Digidata 1322A board and registered by the Clampex
software version 10.2 (Molecular Devices, Sunnyvale, CA,
USA). Data analysis was performed with Clampfit 10
(included in pCLAMP 10).
NMDA receptor-mediated postsynaptic currents (NMDA-
PSCs) were evoked through an NMDA (150 μM)-filled
micropipette coupled to a pressure application system
(PicoPump PV820; World Precision Instruments) positioned
close to the cell soma of the recording cell and injecting
single pulses of 10 ms, 6–10 ψ, applied every 2 min. The
concentration of NMDA in the micropipette, the frequency
of stimulation, injection duration and pressure were chosen
within a range used by others (Khosravani et al., 2008;
Papouin et al., 2012; Laprell et al., 2015) to obtain stable
NMDA-PSCs recordings under control conditions. The
pressure of injection was adjusted from experiment to exper-
iment, as needed to obtain a stable recording, and once
defined, it was not changed up to the end of the experiment.
Individual current recordings were used for analysis, and
their amplitude is depicted in the figure time course panels.
Current tracings in the figures are averages of five consecutive
individual recordings, thus corresponding to averaged
recordings for 10 min before test drug application and for
10 min during peak drug effect. In NMDA-PSC recording
experiments, tetrodoxin citrate (TTX) was added to aCSF
to prevent activity-dependent neurotransmitter release and
minimize presynaptic interference of the recordings.
Afferent-evoked EPSCs mediated by NMDA receptors
(NMDA-EPSCs) were obtained by stimulating the Schaffer
Collateral afferents with 0.2 ms rectangular pulses delivered
once every 15 s through a concentric electrode (Harvard)
placed in the stratum radiatum. Averages of eight consecutive
individual recordings (2 min) were used for analysis. The
aCSF was supplemented with CNQX (10 μM), to block AMPA
and kainate glutamate receptors and gabazine (1 μM), to
block GABAA receptor activity. In paired-pulse experi-
ments, recordings were obtained with the same condition as
single-pulse recordings but two consecutive NMDA-EPSCs
were evoked 100 ms apart.
In all experiments, whenever assessing the influence of a
drug on NMDA receptor-mediated currents, the test drug
was superfused in the aCSF only after at least 10 min of stable
(non-continuous change in the same direction) recordings of
current amplitude. The averaged amplitude values during the
10 min before test drug application were normalized to 100%
(baseline amplitude), to allow comparison of the magnitude
of drug effects in different experiments; the effect of the test
drug was quantified as percentage change from that of
baseline.
Drugs
CGS 21680 (a selective A2A receptor agonist), SCH 58261 (a
selective and competitive A2A receptor antagonist), H-89
dihydrochloride hydrate (a selective inhibitor of cAMP-
dependent protein kinase) and (+)-MK-801 hydrogen ma-
leate (dizocilpine; a non-competitive NMDA antagonist
acting at the ion channel site) were obtained from Sigma-
Aldrich (MO, USA). NMDA, DL-AP5 (a selective NMDA
receptor antagonist) and gabazine (SR-95531; a selective and
competitive GABAA receptor antagonist) were obtained from
Ascent Scientific (Bristol, UK). TTX (sodium-channel blocker)
and CNQX, an antagonist of AMPA/kainate receptors,
were obtained from Tocris Bioscience (Bristol, UK).
Memantine was obtained from Abcam Biochemicals (Cam-
bridge, UK). Isoflurane was obtained from Abbot Laboratories
(Barcelona, Spain) and 1,2-propylenglycol from Merck (NJ,
USA). CGS 21680 (5 mM) and CNQX (100 mM) were pre-
pared as a stock solution in DMSO. TTX (1 mM) was prepared
in water, as well as NMDA (100 μM), DL-AP5 (50 mM),
gabazine (5 mM), MK-801 (10 mM) and memantine
(100 mM). Stock solutions were aliquoted and stored at
20°C until use. Dilutions of these stock solutions to the
final concentration (in aCSF) were made freshly before
each experiment.
Statistical analysis
The data and statistical analysis comply with the recommen-
dations on experimental design and analysis in pharmacol-
ogy (Curtis et al., 2015). Data presented were tested for
normality (Shapiro–Wilk test), and when passed, parametric
analyses were performed. Statistical significance was
evaluated by Students two-tailed paired t-test (parametric) or
Wilcoxon matched-pairs signed rank test (nonparametric),
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while comparing data from periods before and after drug
perfusion. One-way ANOVA, with the Greenhouse–Geisser
correction, followed by Tukey’s multiple comparison post test
(parametric) or Friedman test followed by a Dunn’s multiple
comparisons test (nonparametric) was used for multiple com-
parisons. All statistical analyses were performed in PRISM
GraphPad 6.0 (La Jolla, CA, USA). Statistical significance was
assumed when the P value was below 0.05. All data are pre-
sented as mean ± SEM of n experiments, where n corresponds
to the number of recorded cells from n hippocampal slices
(only one cell for each slice was used in each experiment).
The number of animals used for each set of experiments (N)
is also indicated in the figure legends and Table 1.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked
to corresponding entries in http://www.guidetophar-
macology.org, the common portal for data from the
IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al.,
2018), and are permanently archived in the Concise Guide
to PHARMACOLOGY 2017/18 (Alexander et al., 2017a,b,c).
Results
Activation of adenosine A2A receptors
facilitates NMDA-PSCs in CA1 pyramidal
neurons
To study the actions of A2A receptor activation on NMDA
receptor function, we recorded CA1 pyramidal cells in
whole-cell voltage-clamp mode (Vh = 60 mV) in hippocam-
pal slices. NMDA receptor currents were evoked by pressure
applying NMDA (150 μM, 10 ms) close to the soma of the
recorded cell every 2 min (NMDA-PSCs). After a stable
baseline, the A2A agonist, CGS 21680, was applied at a
concentration (30 nM) selective for A2A receptors (Jarvis et al.,
1989), resulting in an increase in NMDA-PSCs amplitude that
was already visible 2–3 min after starting the changeover of
the solution and reached a maximum after 40 min of perfu-
sion (to 133 ± 13% of baseline level; Figure 1A,D, Table 1).
This is in accordance with the slow kinetics of CGS 21680
binding to its receptor (Hothersall et al., 2017) and the time
for activation of GPCR and kinase-dependent signalling
pathways (Lohse et al., 2008). Following the maximum effect,
the amplitude of NMDA-PSCs started to decrease while
continuously perfusing CGS 21680 and returned to near
pre-control levels (to 115 ± 8.4% of baseline) within
20–30 min after CGS 21680 washout. The effects of the
A2A agonist upon NMDA-PSCs recorded from slices from 5-
to 7- or 8- to 10-week-old rats did not differ appreciably. Both
rise time (measured from 10 to 90% of peak value) and decay
time (decay to 50% of peak value) of NMDA-PSCs were not
changed during perfusion of CGS 21680 (Figure 1B, Table 2)
indicating no change in NMDA-PSCs kinetics (rise time
change from baseline: 7.3 ± 9.4%; decay time change from
baseline: 1.2 ± 9.4%).
To assess if the facilitatory action of CGS 21680 could be
attributed to A2A receptor activation, we tested if this action
could be prevented by the selective A2A antagonist
SCH58261 (100 nM; Zocchi et al., 1996; Rombo et al., 2015).
For this purpose, SCH58261 was added to the perfusion for
at least 30 min before adding the agonist to allow equilibrium
with the antagonist before assessing the effect of the agonist.
The presence of SCH58261 fully prevented the facilitatory
action of CGS 21680 (% change by the agonist: to
105 ± 4.7% of baseline; Figure 1C,D), strongly suggesting a
selective A2A receptor-mediated effect on NMDA-PSCs. By
itself, SCH58261 (100 nM) did not affect NMDA-PSCs
amplitude (% change by the antagonist: to 104 ± 13% of base-
line; Figure 1C,D) suggesting the lack of endogenous action
of adenosine on NMDA receptor-mediated currents, under
the experimental conditions used.
Given that A2A receptor activation with CGS 21680 can
also facilitate AMPA receptor-mediated currents, enhancing
surface expression of Glu1 receptor subunits (Dias et al.,
2012), we excluded the contribution of AMPA receptors for
the recorded PSCs by perfusing the AMPA/kainate receptor
antagonist, CNQX (10 μM), with no effect on NMDA-PSC
(to 99 ± 4.5% of baseline; Figure 1E). Consistent with a selec-
tive NMDA receptor-mediated current, the perfusion of the
NMDA receptor antagonist, DL-AP5 (50 μM), caused a fast
decrease in NMDA-PSCs amplitude to 19 ± 2.3% of baseline
after 10 min of perfusion (Figure 1E).
Knowing that, in the young-adult brain, three quarters of
NMDA receptors are extrasynaptically located (Hardingham
and Bading, 2010), it is likely that extrasynaptic NMDA
receptors greatly contribute to NMDA-PSCs evoked by pres-
sure application of the drug over the neuronal cell body.
Thus, we performed a set of experiments testing the actions
of memantine, a drug that, at selected concentrations,
preferentially blocks extrasynaptic NMDA receptors (Xia
et al., 2010). Compatible with an important contribution of
extrasynaptic NMDARs NMDA receptors to NMDA-PSCs,
perfusion of memantine (1 μM) significantly decreases
NMDA-PSCs to 49 ± 3.2% of baseline (Figure 1F,G). No statis-
tically significant change in NMDA-PSC kinetics was
observed (Table 2). In the presence of memantine, CGS
21680 (30 nM) was still able to increase NMDA-PSCs
(to 152 ± 15% of baseline values recorded before applying
CGS 21680; Figure 1F inset, Figure 1G, Table 1), suggesting
that the facilitatory action of A2A receptors upon NMDA
receptor activity in CA1 pyramidal cells does not occur exclu-
sively through extrasynaptic NMDA receptors.
Table 1
Comparison between the effect of the A2A receptor agonist, CGS
21680 (30 nM), on NMDA currents at CA1 pyramidal neurons
Condition % of change
NMDA-PSCs 133 ± 13 (n = 6; N = 6)
NMDA-PSCs (with MEM) 152 ± 15 (n = 7; N = 4)
NMDA-EPSCs (no MEM) 135 ± 5.2 (n = 11; N = 6)
NMDA-EPSCs (with MEM) 139 ± 9.7 (n = 8; N = 4)
The values represent the action of CGS 21680 (30 nM) on NMDA
currents when compared to baseline level (10 min before drug per-
fusion, P < 0.05, Students paired t-test). The number of experiments
(n) and the number of animals used (N) for each condition are shown
in brackets. The magnitude of the effect did not differ among different
conditions (multiple comparison one-way ANOVA was not statistically
significant, P = 0.82). MEM, memantine.
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Figure 1
A2A receptor activation enhances chemical-evoked NMDA-PSCs. (A) Average normalized time course changes of the effect of 30 nM CGS 21680
(horizontal bar), a selective A2A agonist, on chemically-evoked NMDA-PSCs peak amplitude (n = 6, N = 6). Zero time in the abscissae corresponds
to the time where the first test solution started to be perfused. Data are presented as mean ± SEM. Top insets: tracings (average of five consecutive
currents, 10 min) obtained from representative experiments before (1) and 40 min after (2) CGS 21680 superfusion. *P < 0.05, baseline versus
CGS 21680 effect (Wilcoxon matched-pairs test). (B) Rise time (measured from 10 to 90% of peak value, ms) and decay time (decay to 50% of
peak value, ms) values (left and right panels, respectively) for each individual experiment, with a line connecting values at baseline and after
40 min of CGS 21680 perfusion. Histogram depicts mean ± SEM for each set of values. ns, not significant (rise time, n = 6, P = 0.84 and decay time,
n = 6, P = 0.63, Wilcoxon matched-pairs test). (C) Time course of averaged normalized changes in NMDA-PSC peak amplitude induced by
superfusion of SCH58261 (100 nM) (a selective A2A antagonist) (n = 3, N = 3, left panel) and CGS 21680 (30 nM) while in the presence of
SCH58261 (100 nM) (n = 4, N = 4, right panel). ns, not significant; left panel: baseline versus CGS 21680 (n = 3, P = 0.25); right panel: SCH
58261 versus SCH 58261 + CGS 21680 (n = 4, P = 0.13) (Wilcoxon matched-pairs test). (D) Summary plot showing NMDA-PSC peak amplitude
(pA) of all individual cells shown in (A) and (C). (E) Averaged normalized time course changes of the effect of CNQX (10 μM; upper horizontal bar)
and DL-AP5 (50 μM; bottom horizontal bar) on NMDA-PSC peak amplitude. (F) Average normalized time course changes of the effect of
memantine (MEM; 1 μM, preferentially extrasynaptic NMDA receptor antagonist, upper horizontal bar) and CGS 21680 (30 nM, a selective
A2A agonist, bottom horizontal bar), on chemically-evoked NMDA-PSCs peak amplitude (n = 7, N = 4); data presented as mean ± SEM; inset
(obtained from the period limited by dashed line rectangle) highlights the effect of CGS 21680 normalized to baseline already in the presence
of memantine (baseline recalculated from 40 to 50 min of time course). Right upper inset: sample traces (average of five consecutive currents,
10 min) taken from a representative experiment during baseline (1), memantine superfusion (2) and memantine + CGS 21680 superfusion (3).
Right bottom panel: summary plot showing NMDA-PSC peak amplitude (pA) of all individual cells shown in left panel. (G) Baseline normalized
NMDA-PSC amplitude values for each individual experiment, with a line connecting values from memantine perfusion and memantine + CGS
21680 perfusion. Histogram depicts mean ± SEM for each set of values. *P < 0.05; n = 7, N = 4, one-way ANOVA followed by Tukey’s multiple
comparisons test.
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Activation of adenosine A2A receptors
predominantly facilitates synaptic NMDA
receptor activity
The results presented above suggest that synaptic-located
NMDA receptors are targeted by adenosine A2A receptors. To
confirm this, we evaluated whether CGS 21680 could
enhance NMDA currents when the receptors predominantly
contributing to the currents were indeed synaptic NMDA re-
ceptors. We thus recorded afferent-evoked EPSCs by electri-
cally stimulating in stratum radiatum in the continuous
presence of CNQX (10 μM) and gabazine (5 μM), to block
AMPA/kainate and GABAA receptors respectively. Under such
conditions, the facilitatory effect of the A2A agonist, CGS
21680 (30 nM), was maintained, enhancing NMDA-EPSCs
amplitude to 135 ± 5.2% of baseline (Figure 2A,B, Table 1).
Again, the effect of the A2A agonist upon NMDA-EPSCs
recorded from slices from 5- to 7- or 8- to 10-week-old rats
did not differ significantly.
CGS 21680 may act at presynaptic A2A receptors to en-
hance glutamate release from Schaffer collaterals with impact
upon AMPA receptor-mediated synaptic transmission (Lopes
et al., 2002; Dias et al., 2012). We thus assessed paired pulse
ratios (PPR) to understand whether a presynaptic influence
of A2A receptor could impact upon the NMDA receptor-
mediated synaptic currents. The paired-pulse ratio (PPR = 2nd
EPSCamplitude/1st EPSCamplitude) of two consecutive NMDA-
EPSCs 100 ms apart was analysed, and no significant alter-
ations were detected in the presence of CGS 21680
(99 ± 6.8% of baseline; Figure 2A,B), indicating that A2A
receptor’s action on NMDA-EPSCs does not result from
enhanced release of glutamate.
The CGS 21680 effect was not accompanied by changes in
NMDA-EPSCs kinetics as evidenced by unaltered rise and
decay times of both first and second pulses (rise time change
from baseline: 2.2 ± 3.2% for first pulse and 2.3 ± 6.6% for sec-
ond pulse; decay time change from baseline: 0.1 ± 4.8% for
first pulse and 0.7 ± 3.9% for second pulse; Figure 2C,
Table 2).
As expected, the NMDA-EPSCs were fully blocked by the
perfusion of the NMDA antagonist DL-AP5 (50 μM) (currents
decreased to 7.9 ± 1.2% of baseline; Figure 2D), confirming
the NMDA-mediated nature of the evoked responses.
Altogether, the above experiments suggest that synaptic
NMDA receptors, rather than extrasynaptic ones, are targeted
by A2A receptors. To further assess this possibility, the next
series of experiments were designed to better discriminate
between A2A receptor modulation over synaptic or
extrasynaptic NMDA receptors.
We first evaluated the possibility that peri and
extrasynaptic NMDA receptors could be contributing to the
recorded EPSCs, since they can be recruited either by gluta-
mate spillover into extrasynaptic compartments or during
intense synaptic activity. Thus, we recorded NMDA-EPSCs
(0.067 Hz, paired-pulse) and perfused an open-channel
NMDA receptor blocker, MK-801 (10 μM), to use-dependently
inhibit synaptically evoked NMDA-EPSCs and isolate
extrasynaptically recruited NMDA receptors. In fact, MK-801
perfusion decreased NMDA-EPSCs to 31 ± 1.9% of baseline
(Figure 3A,B), without altering NMDA receptor current kinet-
ics (Table 2), revealing a strong component of synaptic
NMDA receptor activity on electrical-evoked stimulation
conditions.We then perfused CGS 21680 (30 nM) in the pres-
ence of MK-801, aiming to activate A2A receptors in condi-
tions in which extrasynaptic NMDA receptors are the ones
mostly recruited. Under these conditions CGS 2160 caused
no statistically significant changes on NMDA-EPSCs
amplitude (to 111 ± 12.6% of baseline values recorded before
applying CGS 21680; Figure 3A,B) or current kinetics
Table 2










NMDA-PSC (Figure 1A) Baseline 146 ± 36 n = 6, P = 0.84 591 ± 112 n = 6, P = 0.63
CGS 21680 (30 nM) 147 ± 31 571 ± 104
NMDA-PSC (MEM) (Figure 1F) Baseline 188 ± 27 n = 7, P = 0.94 650 ± 124 n = 7, P = 0.94
MEM (1 μM) 190 ± 39 653 ± 149
NMDA-EPSC (1stP) (Figure 2A) Baseline 14 ± 2.8 n = 11, P = 0.95 32 ± 4.2 n = 7, P = 0.81
CGS 21680 14 ± 2.7 32 ± 4.3
NMDA-EPSC (2ndP) (Figure 2A) Baseline 12 ± 1.7 n = 11, P = 0.98 33 ± 4.0 n = 7, P = 0.84
CGS 21680 12 ± 1.6 33 ± 3.8
NMDA-EPSC (MK-801) (Figure 3A) Baseline 22 ± 1.9 n = 10, P = 0.05 37 ± 3.1 n = 10, P = 0.71
MK-801 (10 μM) 23 ± 2.9 36 ± 3.0
MK-801 + CGS 21680 19 ± 1.7 35 ± 3.9
NMDA-EPSC (MEM) (Figure 3D) Baseline 40 ± 4.2 n = 8, P = 0.11 76 ± 5.3 n = 8, P = 0.13
MEM (1 μM) 36 ± 4.7 71 ± 3.8
MEM + CGS 21680 31 ± 5.6 72 ± 5.0
No statistically significant changes were observed in any of the conditions evaluated. 1stP, first pulse; 2ndP, second pulse; MEM: memantine.
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(Table 2), indicating the lack of A2A receptor action upon
extrasynaptic NMDA receptors.
We next performed a set of experiments testing the
actions of memantine on afferent-evoked NMDA-EPSCs.
Perfusion of memantine (1 μM) caused no significant
change in NMDA-EPSCs amplitude (to 96 ± 4.8% of baseline;
Figure 3C,D) or kinetics (Table 2). Consistent with A2A receptor
action being preferentially upon synaptic NMDA receptors,
perfusion of CGS 21680 in the presence of memantine lead to
a facilitation of NMDA-EPSCs to 139 ± 9.7% of baseline values
recorded before perfusion of CGS21680 (Figure 3C,D), with no
change in current kinetics (Table 2), similar to what was
observed in the absence of memantine (Figure 2A, Table 1).
Finally, we tested for the dependency of A2A receptors ac-
tions on classical signalling pathway involving cAMP/PKA
activation (Fredholm et al., 2011). To test this, we first
perfused a selective inhibitor of cAMP-dependent protein ki-
nase, H-89, at a concentration (1 μM) that causes marked in-
hibition of PKA (Bain et al., 2007) without inhibiting other
kinases that could possibly be involved in the synaptic ac-
tions of A2A receptors, such as ERK or MAPK, PKCα or
CAMK (Bain et al., 2007). H-89, per se, had no effect on
NMDA-EPSCs (to 97 ± 2.8% of baseline before H-89,
Figure 3E,F) but completely prevented the action of CGS
21680 on NMDA-EPSCs (to 108 ± 3.8% of baseline before
adding CGS 21680; Figure 3E,F), a finding compatible with
the involvement of canonical pathway for A2A receptors,
the cAMP/PKA signalling cascade, in the modulating effect
of A2A receptors on NMDA receptors.
Altogether, our results strongly indicate a preferential ac-
tion of A2A receptors on synaptic and not extrasynaptic
NMDA receptors via cAMP/PKA signalling.
Figure 2
Adenosine A2A receptor activation potentiates afferent-evoked NMDA receptor-mediated currents (NMDA-EPSCs). (A) Average normalized
time course changes in afferent-evoked NMDA-EPSCs amplitude (first pulse amplitude, open symbols) and PPR (second vs. first pulse ampli-
tude) induced by superfusion of selective A2A receptor agonist, CGS 21680 (30 nM) (horizontal bar). Zero time in the abscissae corresponds
to the time where the first test solution started to be perfused. Data are presented as mean ± SEM (n = 11, N = 6). Right upper inset: sample
traces (average of eight consecutive currents, 2 min) taken from a representative experiment; before (1) and 30 min after CGS 21680 (2)
superfusion; trace showing 30 min after CGS 21680 superfusion was normalized for baseline trace (1 + 2norm) to point out the PPR; the
stimulus artefact for each trace was removed for better visualization. Right bottom panel: summary plot showing baseline-normalized
NMDA-EPSCs peak amplitude (first pulse amplitude, Amp) and PPR (second vs. first pulse amplitude) following addition of CGS 21680.
Circles correspond to individual experiments; triangles represent mean ± SEM. *P < 0.05; ns, not significant (n = 11, N = 6, paired t-test).
(B) Summary plot showing NMDA-EPSC peak amplitude (first pulse amplitude, pA) (left panel) and PPR (second vs. first pulse amplitude)
(right panel) of all individual cells shown in (A). (C) Rise time (measured from 10 to 90% of peak value, ms) and decay time (decay to
50% of peak value, ms) values (left and right panels, respectively) for first and second NMDA-EPSC pulses of each individual experiment,
with a line connecting values at baseline and after 30 min of CGS 21680 perfusion. Histograms depict mean ± SEM for each set of values.
ns, not significant [rise time first pulse, n = 11, P = 0.95; rise time second pulse, n = 11, P = 0.98; decay time second pulse, n = 11, P = 0.84
(Student’s paired t-test) and decay time first pulse, n = 7, P = 0.81, Wilcoxon matched-pairs test]. (D) Averaged normalized time course
changes of the effect of DL-AP5 (50 μM) (horizontal bar) on NMDA-EPSC peak amplitude. Right upper inset: sample traces (average of eight
consecutive currents, 2 min) taken from a representative experiment before (1) and 20 min after DL-AP5 (2) superfusion; the stimulus arte-
fact for each trace was removed for better visualization. Right bottom panel: summary plot showing NMDA-EPSC peak amplitude (first pulse
amplitude, pA) of all individual cells shown in right panel (3: baseline; 4, DL-AP5).
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Figure 3
Synaptic, but not extrasynaptic, NMDA-EPSCs are affected by adenosine A2A receptor activation through cAMP/PKA signalling. (A) Average nor-
malized time course changes of the effect of MK-801 (10 μM, an open-channel NMDA receptor blocker, upper horizontal bar) and CGS 21680
(30 nM, a selective A2A receptor agonist, bottom horizontal bar), on electrically-evoked NMDA-EPSCs peak amplitude (n = 10, N = 5). Zero time
in the abscissae corresponds to the time when the first test solution started to be perfused. Data are presented as mean ± SEM; inset (obtained from
the period limited by dashed line rectangle) highlights the effect of CGS 21680 normalized to baseline already in the presence of MK-801 (baseline
recalculated from 35 to 45 min of time course). Right upper inset: sample traces (average of 8 consecutive currents, 2 min) taken from a represen-
tative experiment during baseline (1), MK-801 superfusion (2) and MK-801 + CGS 21680 superfusion (3); the stimulus artefact for each trace was
removed for better visualization. Right bottom panel: summary plot showing NMDA-EPSC peak amplitude (pA) of all individual cells shown in left
panel. (B) Baseline-normalized NMDA-EPSC amplitude values for each individual experiment, with a line connecting values during MK-801
perfusion and MK-801 + CGS 21680 perfusion. Histogram depicts mean ± SEM for each set of values. *P < 0.05; ns, not significant, n = 10,
N = 5, one-way ANOVA followed by Tukey’s multiple comparisons test. (C) Average normalized time course changes for the effect of memantine
(1 μM, preferentially extrasynaptic NMDA receptor antagonist, upper horizontal bar) and CGS 21680 (30 nM, a selective A2A receptor agonist,
bottom horizontal bar), on electrically-evoked NMDA-EPSCs peak amplitude (n = 8, N = 4); data presented as mean ± SEM; inset (obtained from
the period limited by dashed line rectangle) highlights the effect of CGS 21680 normalized to baseline already in the presence of Memantine
(baseline recalculated from 35 to 45min of time course). Right upper inset: sample traces (average of eight consecutive currents, 2 min) taken from
a representative experiment during baseline (1), memantine superfusion (2) and memantine + CGS 21680 superfusion (3); the stimulus artefact
for each trace was removed for better visualization. Right bottom panel: summary plot showing NMDA-EPSC peak amplitude (pA) of all individual
cells shown in left panel. (D) Baseline-normalized NMDA-EPSC amplitude values for each individual experiment, with a line connecting values dur-
ing memantine perfusion and memantine + CGS 21680 perfusion. Histogram depicts mean ± SEM for each set of values. ns, not significant;
*P < 0.05; n = 8, N = 4, one-way ANOVA followed by Tukey’s multiple comparisons test. (E) Average normalized time course changes of the effect
of H-89 (1 μM, a selective inhibitor of cAMP-dependent protein kinase, upper horizontal bar) and CGS 21680 (30 nM, a selective A2A agonist, bot-
tom horizontal bar), on electrically-evoked NMDA-EPSCs peak amplitude (n = 5, N = 3); data presented as mean ± SEM. Right upper inset: sample
traces (average of eight consecutive currents, 2 min) taken from a representative experiment during baseline (1), H-89 superfusion (2) and H-
89 + CG S21680 superfusion (3); the stimulus artefact for each trace was removed for better visualization. Right bottom panel: summary plot show-
ing NMDA-EPSC peak amplitude (pA) of all individual cells shown in left panel. (F) Baseline-normalized NMDA-EPSC amplitude values for each
individual experiment, with a line connecting values during H-89 perfusion and H-89 + CGS 21680 perfusion. Histogram depicts mean ± SEM
for each set of values. ns, not significant; n = 5, N = 5, Kruskal–Wallis test followed by Dunn’s multiple comparisons test.
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Discussion
The main finding in the present work is that adenosine A2A
receptors facilitate postsynaptic NMDA currents in CA1 pyra-
midal neurons and that this facilitation preferentially occurs
at the synaptic rather than extrasynaptic level.
A2A receptors at the hippocampus are scarcely distrib-
uted but are known to affect hippocampal synaptic
transmission at different levels. A predominant role of hip-
pocampal A2A receptors is to facilitate the action of other
neuromodulators, such as BDNF (Diógenes et al., 2004),
or receptors for neurotransmitters, such as glutamate AMPA
receptors (Dias et al., 2012) and mGlu5 receptors (Tebano
et al., 2005). Presynaptically, A2A receptors are also known
to increase glutamate release, although in young rats this
action is small and mostly results from a blockade of A1
receptor-mediated inhibitory effect (Lopes et al., 2002). In
addition, A2A receptors at the hippocampus also enhance
GABA release (Cunha and Ribeiro, 2000), an action that
is synapse-specific resulting in a disinhibition of gluta-
matergic neurons (Rombo et al., 2015). All these A2A
receptor-mediated actions may impact synaptic plasticity
(Dias et al., 2013a; Sebastião and Ribeiro, 2015), as demon-
strated by A2A receptor facilitation of LTP (Costenla et al.,
1999; Dias et al., 2012) and post-ischaemia plasticity phe-
nomena (Dias et al., 2013b). The influence of A2A receptors
on hippocampal NMDA receptors has been much less
explored. There is, however, evidence on dentate gyrys-
CA3 synapses that A2A receptor activation unmasks a new
form of NMDA receptor-dependent LTP that most likely
occurs at the postsynaptic level (Rebola et al., 2008).
However, evidence for a direct postsynaptic influence of
A2A receptors upon NMDA receptors was until now lacking.
The data obtained in the present study have revealed this
missing link, clearly showing that NMDA receptors are tar-
gets for A2A receptors likely through the canonical
cAMP/PKA signalling pathway, and importantly, we showed
that this action is evident in young animals and occurs
predominantly at synaptic rather than extrasynaptic recep-
tors. Furthermore, this action was clearly detected in the
CA1 hippocampal area where synaptic plasticity mostly
depends upon NMDA receptors.
A2A receptors are known to affect memory tasks depen-
dent on intact hippocampal activity, an action that seems
to depend on the age and physiological state of the animal.
Thus, while in young animals, A2A receptor blockade dis-
turbs hippocampal-dependent conditional learning as well
as prevents the concomitant increase in synaptic potentials
at the hippocampus (Fontinha et al., 2009), supporting a
facilitatory action of A2A receptor synaptic plasticity and
memory acquisition, in aged animals, where spurious LTP
occurs at Schaffer CA1 synapses (Diógenes et al., 2007),
A2A receptor blockade restores plasticity towards normal
values (Costenla et al., 2011). The same also occurs in
chronically stressed animals where A2A receptor blockade
has been shown to counteract exacerbated plasticity and
to facilitate learning (Batalha et al., 2013), thus suggesting
a negative influence of A2A receptors upon hippocampal-
dependent tasks. This apparent contradiction on the influ-
ence of A2A receptors in learning in young versus aged
and/or diseased animals may result from the different roles
of A2A receptor in heathy young animals, aged animals or
under disease conditions (Sebastião and Ribeiro, 2009).
The same is also known to occur with NMDA receptors.
Indeed, it is widely accepted that synaptic NMDA receptor
activation is necessary for several forms of memory
encoding and retrieval. Thus, our results showing that A2A
receptors can facilitate synaptic NMDA receptors in young
animals help to explain the negative effects of A2A receptor
antagonists on certain learning paradigms in healthy
young animals.
In contrast, neurodegenerative conditions are known to
increase activation of NMDA receptors and calcium-
permeable AMPA receptors, leading to hippocampal synaptic
plasticity impairment (Diógenes et al., 2012; Ferreira et al.,
2017; Tanqueiro et al., 2018). There is plenty of evidence that
under pathological conditions, A2A receptor signalling is
exacerbated, which contributes to pathogenesis and leads to
early cognitive and synaptic dysfunction as well as neurode-
generation (Canas et al., 2009; Cognato et al., 2010; Batalha
et al., 2013; Kadowaki-Horita et al., 2013; Kaster et al., 2015;
Li et al., 2015a,b; Hu et al., 2016; Laurent et al., 2016; Viana
da Silva et al., 2016). Under such pathological conditions,
A2A receptor blockade restores learning and/or memory
(Canas et al., 2009; Cognato et al., 2010; Batalha et al., 2013;
Kadowaki-Horita et al., 2013; Kaster et al., 2015; Li et al.,
2015b; Viana da Silva et al., 2016). A2A receptor-mediated dys-
functions may even precede NMDA receptor dysfunction
(Viana da Silva et al., 2016). In most of the above-mentioned
studies, the dysfunctional A2A receptor activity predomi-
nantly occurs at the presynaptic level, enhancing glutamate
release, therefore, being prone to indirectly facilitate NMDA
receptor activation, which under pathological conditions
may provide a positive feedback loop towards neurodegener-
ation. Interestingly, in healthy aged animals, enhanced
synaptic plasticity and NMDA receptor activation seem to
compensate cognitive decline (Pinho et al., 2017). One may
thus think that while in disease conditions, A2A receptors
exacerbate excitotoxicity and, under non-diseased condi-
tions, a facilitatory action of A2A receptors on several steps
of excitatory synaptic transmission may compensate some
loss of function in the aged. Importantly, since synaptic and
extrasynaptic NMDA receptors have different roles in plastic-
ity and in neurodegeneration, with the extrasynaptic NMDA
receptors being more prone to gate neurodegeneration and
synaptic NMDA receptors mostly involved in synaptic
plasticity (Hardingham and Bading, 2010), a drug that could
selectively facilitate synaptic NMDA receptors without
affecting extrasynaptic ones could be a candidate to selec-
tively promote plasticity with minimal consequences on
degeneration. Selective A2A receptor agonists may prove to
usefully fulfil this task.
In conclusion, our results showing that A2A receptors
predominantly affect synaptic NMDA receptors thus sug-
gest that, at least in young animals, A2A receptor activation
may contribute to a shift in the dual role of NMDA recep-
tors towards enhancement of synaptic plasticity. Further
studies in healthy aged animals are desirable to clarify
weather this selective influence of A2A receptors on synap-
tic NMDA receptors, rather than extrasynaptic receptors,
may prove beneficial to enhance cognition without trigger-
ing neurodegeneration.
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